Allergan Stock Downgraded: What You Need to Know
Every day, Wall Street analysts upgrade some stocks, downgrade others, and "initiate coverage" on a few more. But do these analysts even know what they're talking about? Today, we're taking one high-profile Wall Street pick and putting it under the microscope...
With its shares down 13% over the last 12 months, 2017 has not been kind to Allergan (NYSE: AGN) stock -- and now, It looks like things may be starting to get even worse. This morning, analysts at Argus Research sounded a warning note on Allergan's growth prospects and downgraded the stock from buy to hold.
Here are three things you need to know.
Source: Fool.com
